Global Hepatitis Drug Market & Clinical Trials Insight 2023
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Hepatitis Drug Market & Clinical Trials Insight 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs.
“Global Hepatitis Drug Market & Clinical Trials Insight 2023” report highlights:
The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management.
With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection.
The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.
“Global Hepatitis Drug Market & Clinical Trials Insight 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs.
“Global Hepatitis Drug Market & Clinical Trials Insight 2023” report highlights:
- Prevalence of Hepatitis Infection
- Available Drug Classes for Hepatitis Drug
- Global Hepatitis Drug Market Analysis
- Global Hepatitis (A,B,C,D & E) Drug Clinical Pipeline Insight
- Marketed Hepatitis Drug Clinical Insight by Drug Class
- Future Perspective of Hepatitis Therapeutics
The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management.
With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection.
The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.
1. INTRODUCTION TO HEPATITIS DISEASE
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. GLOBAL PREVALENCE OF HEPATITIS INFECTION
3. AVAILABLE DRUG CLASSES FOR HEPATITIS DISEASE TREATMENT
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase Inhibitors Therapy
3.4 Toll like Receptor Agonists Therapy
4. GLOBAL HEPATITIS DRUG MARKET ANALYSIS
4.1 Introduction
4.2 Global Hepatitis Drug Market Insight
5. GLOBAL HEPATITIS DRUG MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Market Challenges
6. FUTURE PERSPECTIVE OF HEPATITIS THERAPEUTICS
7. GLOBAL HEPATITIS DRUG CLINICAL PIPELINE OVERVIEW
7.1 Hepatitis A
7.2 Hepatitis B
7.3 Hepatitis C
7.4 Hepatitis D
7.5 Hepatitis E
8. HEPATITIS A DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (5 DRUGS)
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-III
9. MARKETED HEPATITIS A DRUG CLINICAL INSIGHT BY DRUG CLASS (12 DRUGS)
10. HEPATITIS B DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (134 DRUGS)
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered
11. MARKETED HEPATITIS B DRUG CLINICAL INSIGHT BY DRUG CLASS (46 DRUGS)
12. HEPATITIS C DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (145 DRUGS)
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered
13. MARKETED HEPATITIS C DRUG CLINICAL INSIGHT BY DRUG CLASS (25 DRUGS)
13.1 ZEPATIER
13.2 Harvoni
13.3 Victrelis
13.4 Copegus
13.5 Sovaldi
13.6 Vanihep
13.7 Incivek
13.8 Olysio
13.9 VIEKIRA
13.10 Infergen
13.11 Viekirax
13.12 Epclusa
13.13 Ximency
13.14 Daclatasvir + Asunaprevir Combination
13.15 Peginterferon Alfa-2b (Y-shaped pegylation)
13.16 Golotimod
13.17 Algeron
13.18 Pegetron
13.19 Rebetron
13.20 IBAVYR
13.21 Reiferon Retard
13.22 Reiferon - Interferon Alpha-2a Biosimilar
13.23 Interferon Alpha-2a
13.24 Glycyron Tablets
13.25 Daklinza
14. HEPATITIS D DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (4 DRUGS)
14.1 Research
14.2 Preclinical
14.3 Phase-II
15. HEPATITIS E DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS ( 2 DRUGS)
15.1 Preclinical
15.2 Phase-I
16. MARKETED HEPATITIS E DRUG CLINICAL INSIGHT BY DRUG CLASS (1 DRUG)
17. MULTIPLE HEPATITIS DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (31 DRUGS)
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Preregistration
18. MARKETED MULTIPLE HEPATITIS DRUG CLINICAL INSIGHT BY DRUG CLASS (26 DRUGS)
19. COMPETITIVE LANDSCAPE
19.1 Arbutus Biopharma
19.2 Biostar Pharmaceuticals
19.3 Bristol-Myers Squibb
19.4 GlaxoSmithKline
19.5 Gilead Sciences
19.6 Enanta
19.7 Achillion
19.8 Presidio
19.9 Benitec Biopharma
19.10 Janssen Pharmaceuticals
19.11 AbbVie
19.12 Merck
19.13 Novira Therapeutics
19.14 Contravir
19.15 VBI Vaccines
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. GLOBAL PREVALENCE OF HEPATITIS INFECTION
3. AVAILABLE DRUG CLASSES FOR HEPATITIS DISEASE TREATMENT
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase Inhibitors Therapy
3.4 Toll like Receptor Agonists Therapy
4. GLOBAL HEPATITIS DRUG MARKET ANALYSIS
4.1 Introduction
4.2 Global Hepatitis Drug Market Insight
5. GLOBAL HEPATITIS DRUG MARKET DYNAMICS
5.1 Favorable Market Parameters
5.2 Market Challenges
6. FUTURE PERSPECTIVE OF HEPATITIS THERAPEUTICS
7. GLOBAL HEPATITIS DRUG CLINICAL PIPELINE OVERVIEW
7.1 Hepatitis A
7.2 Hepatitis B
7.3 Hepatitis C
7.4 Hepatitis D
7.5 Hepatitis E
8. HEPATITIS A DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (5 DRUGS)
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-III
9. MARKETED HEPATITIS A DRUG CLINICAL INSIGHT BY DRUG CLASS (12 DRUGS)
10. HEPATITIS B DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (134 DRUGS)
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered
11. MARKETED HEPATITIS B DRUG CLINICAL INSIGHT BY DRUG CLASS (46 DRUGS)
12. HEPATITIS C DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (145 DRUGS)
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered
13. MARKETED HEPATITIS C DRUG CLINICAL INSIGHT BY DRUG CLASS (25 DRUGS)
13.1 ZEPATIER
13.2 Harvoni
13.3 Victrelis
13.4 Copegus
13.5 Sovaldi
13.6 Vanihep
13.7 Incivek
13.8 Olysio
13.9 VIEKIRA
13.10 Infergen
13.11 Viekirax
13.12 Epclusa
13.13 Ximency
13.14 Daclatasvir + Asunaprevir Combination
13.15 Peginterferon Alfa-2b (Y-shaped pegylation)
13.16 Golotimod
13.17 Algeron
13.18 Pegetron
13.19 Rebetron
13.20 IBAVYR
13.21 Reiferon Retard
13.22 Reiferon - Interferon Alpha-2a Biosimilar
13.23 Interferon Alpha-2a
13.24 Glycyron Tablets
13.25 Daklinza
14. HEPATITIS D DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (4 DRUGS)
14.1 Research
14.2 Preclinical
14.3 Phase-II
15. HEPATITIS E DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS ( 2 DRUGS)
15.1 Preclinical
15.2 Phase-I
16. MARKETED HEPATITIS E DRUG CLINICAL INSIGHT BY DRUG CLASS (1 DRUG)
17. MULTIPLE HEPATITIS DRUG CLINICAL TRIALS INSIGHT BY PHASE & DRUG CLASS (31 DRUGS)
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Preregistration
18. MARKETED MULTIPLE HEPATITIS DRUG CLINICAL INSIGHT BY DRUG CLASS (26 DRUGS)
19. COMPETITIVE LANDSCAPE
19.1 Arbutus Biopharma
19.2 Biostar Pharmaceuticals
19.3 Bristol-Myers Squibb
19.4 GlaxoSmithKline
19.5 Gilead Sciences
19.6 Enanta
19.7 Achillion
19.8 Presidio
19.9 Benitec Biopharma
19.10 Janssen Pharmaceuticals
19.11 AbbVie
19.12 Merck
19.13 Novira Therapeutics
19.14 Contravir
19.15 VBI Vaccines
LIST OF FIGURES
Figure 1-1: Pathogenesis of Liver by the Exposure of Different Factors
Figure 1-2: Historical Development of Hepatitis Drug Treatment
Figure 1-3: Factors which are Responsible for Hepatitis Disease Development
Figure 2-1: Global - Incidence & Mortality Cases of Hepatitis B Infection (Million), 2015
Figure 2-2: Global - Incidence & Mortality Cases of Hepatitis C Infection (Million), 2015
Figure 3-1: Interferon Alpha - Mechanism of Action for Treating Liver Disease
Figure 3-2: Toll like Receptors & Activation of Antiviral Innate and Adaptive Immune Responses in Hepatitis Virus Infection
Figure 4-1: Global- Hepatitis B & C as Cause for Liver Cancer (%)
Figure 4-2: Global - Hepatitis Drug Market (US$ Billion), 2016 - 2023
Figure 4-3: Global- Hepatitis B Drug Market (US$ Billion), 2016-2023
Figure 4-4: Global - Hepatitis C Drug Market (US$ Billion), 2016-2023
Figure 5-1: Favorable Parameters to Hepatitis Drug Treatment Market Growth
Figure 5-2: Challenges to Hepatitis Therapeutic Market Growth
Figure 6-1: Future Landscape of Hepatitis Infection Treatment Research
Figure 7-1: Global - Hepatitis A Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-2: Global - Hepatitis A Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-3: Global - Hepatitis B Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-4: Global - Hepatitis B Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-5: Global Hepatitis C Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global Hepatitis C Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-7: Global - Hepatitis D Drug Clinical Pipeline By (%), 2017 till 2023
Figure 7-8: Global - Hepatitis D Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-9: Global - Hepatitis E Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-10: Global - Hepatitis E Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 1-1: Pathogenesis of Liver by the Exposure of Different Factors
Figure 1-2: Historical Development of Hepatitis Drug Treatment
Figure 1-3: Factors which are Responsible for Hepatitis Disease Development
Figure 2-1: Global - Incidence & Mortality Cases of Hepatitis B Infection (Million), 2015
Figure 2-2: Global - Incidence & Mortality Cases of Hepatitis C Infection (Million), 2015
Figure 3-1: Interferon Alpha - Mechanism of Action for Treating Liver Disease
Figure 3-2: Toll like Receptors & Activation of Antiviral Innate and Adaptive Immune Responses in Hepatitis Virus Infection
Figure 4-1: Global- Hepatitis B & C as Cause for Liver Cancer (%)
Figure 4-2: Global - Hepatitis Drug Market (US$ Billion), 2016 - 2023
Figure 4-3: Global- Hepatitis B Drug Market (US$ Billion), 2016-2023
Figure 4-4: Global - Hepatitis C Drug Market (US$ Billion), 2016-2023
Figure 5-1: Favorable Parameters to Hepatitis Drug Treatment Market Growth
Figure 5-2: Challenges to Hepatitis Therapeutic Market Growth
Figure 6-1: Future Landscape of Hepatitis Infection Treatment Research
Figure 7-1: Global - Hepatitis A Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-2: Global - Hepatitis A Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-3: Global - Hepatitis B Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-4: Global - Hepatitis B Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-5: Global Hepatitis C Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global Hepatitis C Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-7: Global - Hepatitis D Drug Clinical Pipeline By (%), 2017 till 2023
Figure 7-8: Global - Hepatitis D Drug Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 7-9: Global - Hepatitis E Drug Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-10: Global - Hepatitis E Drug Clinical Pipeline by Phase (Number), 2017 till 2023
LIST OF TABLES
Table 3-1: Protease Inhibitors in Development for Hepatitis Disease Treatment
Table 3-2: Toll like Receptor Affecting Immunopathogenesis of Hepatitis Virus Infection
COMPANIES MENTIONED
Arbutus Biopharma,
Biostar Pharmaceuticals,
Bristol-Myers Squibb,
GlaxoSmithKline,
Gilead Sciences,
Enanta,
Achillion,
Presidio,
Benitec Biopharma,
Janssen Pharmaceuticals,
AbbVie,
Merck,
Novira Therapeutics,
Contravir,
VBI Vaccines
Table 3-1: Protease Inhibitors in Development for Hepatitis Disease Treatment
Table 3-2: Toll like Receptor Affecting Immunopathogenesis of Hepatitis Virus Infection
COMPANIES MENTIONED
Arbutus Biopharma,
Biostar Pharmaceuticals,
Bristol-Myers Squibb,
GlaxoSmithKline,
Gilead Sciences,
Enanta,
Achillion,
Presidio,
Benitec Biopharma,
Janssen Pharmaceuticals,
AbbVie,
Merck,
Novira Therapeutics,
Contravir,
VBI Vaccines
